Page 6,579«..1020..6,5786,5796,5806,581..6,5906,600..»

Successful Growth of BioDiem's Virus in VIVALIS EB66(R) Cell Line

Posted: Published on August 23rd, 2012

ROUSSAY, FRANCE--(Marketwire -08/21/12)- Successful growth of BioDiem's Virus in VIVALIS EB66() Cell Line Highlights: * BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66() cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known techniques to demonstrate the creation of new, 'disarmed' viruses (vectors) carrying foreign antigens that can be customized to fight specific diseases. * Both BioDiem's LAIV virus and VIVALIS' EB66 have produced vaccines which have been through Phase II clinical trials, facilitating commercialisation. Melbourne (Australia), Nantes (France), 21 August 2012: Australian infectious disease therapy and vaccine development company BioDiem Ltd (BDM.AX) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66( )cell line. The next stage of the collaboration between BioDiem and VIVALIS will use known techniques to modify the LAIV virus to demonstrate and optimize the methodology for making a customizable "vector" which could be used by vaccine developers for the development of new vaccines targeting other specific diseases. Priority disease targets include nasopharyngeal carcinoma and respiratory syncytial … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Successful Growth of BioDiem's Virus in VIVALIS EB66(R) Cell Line

TiGenix : Business Update & Financial Highlights for the First Half of 2012

Posted: Published on August 23rd, 2012

Regulated information August 23, 2012 TiGenix Business Update & Financial Highlights for the First Half of 2012 Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012. Business highlights Financial highlights "The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601." Business update Commercial roll-out of ChondroCelect continues to gain momentum ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive … Continue reading

Comments Off on TiGenix : Business Update & Financial Highlights for the First Half of 2012

Stem cell research may have application to treat autism

Posted: Published on August 23rd, 2012

SACRAMENTO, Calif. Rydr Rudgers suffers from cerebral palsy. He couldnt move or talk before a cord blood stem cell treatment undertaken during a Duke University study. His doctor, Michael Chez, M.D. is medical director of Pediatric Neurology at Sutter Neuroscience Institute. He is now heading up the first stem cell clinical trial on autism and hopes for similar results. Dr. Chez says autism shares some of the same symptoms as cerebral palsy and that there is plenty of anecdotal evidence that using cord blood stem cells from the patients own umbilical cord can regenerate brain cells. The study which will employ placebos will determine scientifically whether such treatments make improvements in young autism patients. Sutter Neuroscience Institute got FDA approval for the landmark study and will enroll 30 kids with autism age 2 to 7 to receive injections of their own stem cells. Most parents are given the option of saving their childrens ubilical cords after birth. Elisa Rudgers is glas she did. Now four years old, Rydr is walking, talking and eating on his own. That wasnt possible without three stem cell therapy injections over several years. After each injection he made a marked improvement in motor skills. Its … Continue reading

Comments Off on Stem cell research may have application to treat autism

FDA approves generic Actos in the midst of brand name lawsuits

Posted: Published on August 23rd, 2012

Contributor (888) 633-0360 Last Friday, the FDA approved a generic version of type 2 diabetes drug Actos. Even if you dont suffer from the adult-onset disease, youve likely heard the name Actos in the news. Hundreds of people have sued the drugs manufacturer, Takeda Pharmaceuticals, for failing to warn of serious adverse side effects, including the risk of bladder cancer. As you may have also heard, and as MedicineNet states, Generic drugs are copies of brand-name drugs that have exactly the same dosage, intended use, effects, side effects, route of administration, risks, safety, and strength as the original drug. In other words, their pharmacological effects are exactly the same as those of their brand-name counterparts. That being said, West Virginia-based Mylan Pharmaceuticals, the maker of the generic Actos, was forced to add a bladder cancer warning to its label. And since studies have also shown that Actos may cause heart failure in some individuals, the generic versions label warns of this as well. If your doctor prescribes the generic version of Actos, if your insurance company only approves your pharmacy to give you the generic version of Actos, or if you take the generic version because its less expensive, please … Continue reading

Posted in Drug Side Effects | Comments Off on FDA approves generic Actos in the midst of brand name lawsuits

FDA warns of dangerous dietary supplements

Posted: Published on August 23rd, 2012

Story Created: Aug 22, 2012 at 3:33 PM EDT Story Updated: Aug 22, 2012 at 3:33 PM EDT The agency has issued a safety alert to warn consumers about the dangers of the supplements. They are both marketed as natural dietary supplements but the FDA claims they have potentially dangerous active ingredients that aren't listed on their labels. The supplements are used to treat arthritis, osteoporosis, muscle pain, bone cancer and a host of other ailments. They are manufactured in Mexico by Riger Naturals, but sold in the United States in some stores, Internet sites and flea markets. Most are labeled in Spanish but there could be versions with English labels. The FDA is working closely with the Mexican government and says the Mexican Ministry of Health issued a health warning to the public and ordered Riger Naturals to recall the products. In June, the FDA issued its first initial warning to consumers about Reumofan Plus based on preliminary laboratory tests. But after receiving increased reports of health problems, confirming drug ingredients and finding similar ingredients in Reumofan Plus Premium, officials decided to issue a second warning. "Consumers taking these products are urged to immediately consult with their doctor to … Continue reading

Posted in Drug Side Effects | Comments Off on FDA warns of dangerous dietary supplements

Drugs and alcohol in U.S. high schools

Posted: Published on August 23rd, 2012

CHICOPEE, Mass. (WWLP) - According to a new study, drug and alcohol use in U.S. high schools is more common than you may think. "I haven't seen anybody smoke or drink, but I've heard stories of people bringing alcohol into school--like in little nips and everything", said recent high school graduate Vera Kalatina of Agawam. The National Center on Addiction and Substance Abuse at Columbia University is reporting that 9 out of 10 high school students say they have classmates who smoke, drink, or use drugs during school hours. This issue is not just limited to public schools either. Teens at private schools also reported that drugs are in their hallways too--that's a 50%increase from last year. Many teens agree it's problem that will, most likely, not solve itself. "I feel it's hard, but it's something that's probably just going to keep happening and keep happening more", said Jared Grabowski of Westfield. However in some parts of Western Massachusetts, statistics show that drug use in the schools is not an issue. For example, in Hampshire County, 88% of students surveyed in 2011 said that they have not used drugs or alcohol while at school. That's based on data from the … Continue reading

Posted in Drugs | Comments Off on Drugs and alcohol in U.S. high schools

Study: One in 5 drink, smoke or do drugs during school day

Posted: Published on August 23rd, 2012

Doug Menuez/Getty Images A new survey found that nearly one in five students do drugs, drink or smoke cigarettes during the school day. Marijuana was the drug easiest to buy on school grounds, kids said. They may be in the classroom, but their heads are somewhere else. Nearly one in five students do drugs, drink or smoke cigarettes during the school day, according to a jarring new survey by the National Center on Addiction and Substance Abuse at Columbia University. While the revelation that 17% of high school students may be half in the bag on any given day may come as a shock to some parents or teachers, its old news to the 1,000 students surveyed. Some 86% told survey-takers that they were well aware their glassy-eyed classmates were stoned or drunk. It takes a teen to know whats going on in the teen world, said Emily Feinstein, who directed the 17th annual survey. Half of the students polled said they know who deals drugs at school and where students can go nearby to get high. Marijuana was the drug easiest to buy on school grounds, students said, followed by prescription drugs, cocaine and ecstasy. The survey of 12- … Continue reading

Posted in Drugs | Comments Off on Study: One in 5 drink, smoke or do drugs during school day

Most teens surveyed say classmates drink, use drugs on campus

Posted: Published on August 23rd, 2012

If one of parents biggest worries is that their teenagers are exposed to drugs and alcohol at school, their fears are justified: Eighty-six percent of high school students say their classmates are smoking, drinking or using drugs during the school day, according to a national survey. The 17thannual back-to-school survey by the National Center of Addiction and Substance Abuse at Columbia University shows that tobacco, alcohol and drug use are pervasive and relentless fixtures in the teen world, Joseph A. Califano, founder and chairman of the center, writes in a statement accompanying the survey results. He called the results profoundly disturbing. Some of the reasons: --Students estimate that 17% of their classmates are drinking, using drugs or smoking during the school day. And about half say theres a place on or near campus where this happens. --Teens estimated that 47% of classmates drink alcohol; 40% use drugs; 30% smoke cigarettes. --Sixty percent of high school students and 32% of middle school students say students keep or sell drugs on campus. (In private high schools, 54% said this happens.) The high school figure has been at least 60% in seven of the last eight years. --Forty-four percent say they know someone … Continue reading

Posted in Drugs | Comments Off on Most teens surveyed say classmates drink, use drugs on campus

MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine

Posted: Published on August 22nd, 2012

Public release date: 22-Aug-2012 [ | E-mail | Share ] Contact: Mike Wolterbeek mwolterbeek@unr.edu University of Nevada, Reno RENO, Nev. A novel treatment in development at the University of Nevada School of Medicine for the most common form of muscular dystrophy is advancing towards human trials with a $308,000 boost from the Muscular Dystrophy Association. The grant will be used to expand successful research by Associate Professor of Pharmacology Dean Burkin that has shown his laminin-111 protein therapy prevents the onset of the devastating neuromuscular disease in mouse models. "The early results for laminin-111 as a therapeutic agent for (Duchenne muscular dystrophy) are really exciting," Sanjay Bidichandani, MDA vice president of research, said. "We are eager to see this research go forward." Duchenne muscular dystrophy is a lethal genetic disease that affects one in 3,500 newborn boys and is caused by mutations in the gene encoding dystrophin. There is no effective treatment or cure. At the time of diagnosis, DMD patients usually have developed significant muscle disease. The three-year grant will help determine if Burkin's therapy is effective at preventing or reversing disease progression after onset. "What we aim to discover now is if this therapy is effective at preventing … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine

Why muscles go wrong in Duchenne muscular dystrophy

Posted: Published on August 22nd, 2012

ScienceDaily (Aug. 22, 2012) University of Maryland (UM) researchers and collaborators report in the journal Science Signaling that skeletal muscle degeneration in Duchenne muscular dystrophy (DMD) is worsened by stiffening of the microtubule cytoskeleton that provides structure inside muscle cells. Duchenne muscular dystrophy occurs in about 1 out of every 3,600 male infants and "worsens quickly," according to the U.S. National Library of Medicine. It is caused by a defective gene for a protein (dystrophin) in the muscles and there is no known cure. The unique interdisciplinary study identifies new potential therapeutic targets for intervening in this devastating disease, says Christopher Ward, PhD, associate professor at the UM School of Nursing and senior author of the study. "We show that an enhancement in the microtubule network structure, a stiffening, underlies dysfunction in Duchenne muscular dystrophy," says Ward. The study is a follow-up to the discovery by Ward and others (Prosser et al. Science, 333, 2011) of a new signaling pathway called X-ROS signaling. It is a pathway by which the mechanic stress of stretching a muscle cell acts through the microtubule network to activate a small burst of reactive oxygen species (ROS), which is also known as free radicals. "In … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Why muscles go wrong in Duchenne muscular dystrophy

Page 6,579«..1020..6,5786,5796,5806,581..6,5906,600..»